|11/25/13||OraSure Technologies Reaffirms 4th Quarter 2013 Financial Guidance|
|BETHLEHEM, Pa., Nov. 25, 2013 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (Nasdaq:OSUR) announced today that it is reaffirming its fourth quarter 2013 financial guidance, which the Company last updated in a press release it issued on November 21, 2013.
This reaffirmation is being made after the Company learned today that a customer of its molecular collection systems subsidiary, DNA Genotek, received a warning letter from the U.S. Food and Drug Administration (FDA) requesting that this cu... |
|11/21/13||OraSure Technologies Announces New Agreement with Thermo Fisher Scientific for Development and Distribution of Fully Automated Oral Fluid Drugs of Abuse Assays|
|OraSure Transitions From Prior Oral Fluid Assay Collaboration
BETHLEHEM, Pa. – November 21, 2013 – OraSure Technologies, Inc. (NASDAQ:OSUR) announced today that it has reached an agreement with Thermo Fisher Scientific (Thermo Fisher), to develop and supply up to 12 homogenous fully automated oral fluid drugs of abuse assays to be used with a new Intercept® oral fluid specimen collection device. OraSure will have the right to purchase and resell the assays in the U.S. and in certain foreign cou... |
|11/21/13||OraSure Technologies Terminates Oral Fluid Drugs of Abuse Assay Collaboration with Roche Diagnostics|
|Updated Financial Guidance Announced for Fourth Quarter
BETHLEHEM, Pa. – November 21, 2013 – OraSure Technologies, Inc. (NASDAQ:OSUR) announced today that its assay collaboration agreement with Roche Diagnostics has been terminated. As part of the termination, Roche will continue to supply certain of the assays developed under that collaboration on a transitional basis for use with OraSure’s existing Intercept® collection device.
Under the termination agreement, Roche will make an initial pay... |
|11/07/13||OraSure Technologies to Present at Canaccord|Genuity's Medical Technology & Diagnostics Forum|
|BETHLEHEM, Pa., Nov. 7, 2013 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (Nasdaq:OSUR) today announced that Ronald H. Spair, COO & CFO, will speak to the investment community at Canaccord|Genuity's Medical Technology & Diagnostics Forum in New York City. The conference will be simultaneously webcast over the Internet.
Mr. Spair is scheduled to speak November 14, at approximately 11:00 am Eastern Time (8:00 am Pacific Time). Interested investors can access the live webcast of the p... |